Syndax Pharmaceuticals Drops After Phase 2 IPF Trial of Axatilimab Misses Primary Endpoint

The Quick Take

• Syndax Pharmaceuticals (SNDX) announced its MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis failed to meet its primary endpoint.
• The primary endpoint was annualised rate of FVC decline; the miss signals axatilimab's efficacy does not extend from its approved cGVHD indication to IPF.
• Shares fell sharply, reflecting the market's re-pricing of the drug's pipeline optionality beyond the chronic graft-versus-host disease indication.

Syndax had been building a thesis around axatilimab as a multi-indication anti-fibrotic agent following its commercial approval in chronic graft-versus-host disease. The IPF expansion was a high-optionality bet: idiopathic pulmonary fibrosis is a large and underserved market with limited treatment options beyond nintedanib and pirfenidone. A positive Phase 2 signal would have materially expanded the drug's addressable market and likely triggered a significant re-rating. The primary endpoint failure closes that avenue and forces investors to recalibrate the pipeline's risk-adjusted value entirely.

The failure carries a specific biological implication. Axatilimab works by blocking the CSF-1 receptor, which regulates macrophage and fibroblast activity. In cGVHD, this mechanism is well-validated; in IPF, the role of CSF-1R-driven macrophage polarisation is more complex and less clearly tied to disease progression. The negative outcome suggests the mechanistic hypothesis for IPF was either incorrect or that the patient population and dosing in MAXPIRe were not optimally configured to detect a meaningful signal in this distinct fibrotic indication.

For investors, the key question now is the commercial trajectory of the cGVHD indication alone. Syndax had reported growing prescriptions since launch, and the drug's orphan status provides pricing power in that narrower indication. However, the original valuation included meaningful probability of IPF success. With that removed, analyst price-target revisions are likely. Short interest may spike as hedge funds re-evaluate whether remaining pipeline assets — including next-generation CSF-1R inhibitors — can justify the current market capitalisation. Investors should watch the Q3 earnings call for cGVHD volume uptake commentary.

Synthesized from 1 source.